Latest Conference Coverage

Pooled Phase 3 Data Suggests 50 mg Daridorexant as Most Effective Starting Dose in Insomnia

Daridorexant, an FDA-approved dual orexin receptor antagonist, had a dose-response relationship observed at month 1 on all 4 efficacy end points for all doses tested.

Qualitative Interviews Reveal Impact of Fatigue and Sleepiness in Obstructive Sleep Apnea

A recent study showed that patients with obstructive sleep apnea experience significant negative impacts on their physical, social, and emotional functioning.

NeuroVoices: James Rowley, MD, on SLEEP 2024 and the Direction of the AASM

The pulmonologist at Rush Health and immediate past president of the American Academy of Sleep Medicine provided perspective on some of the intriguing changes to sleep medicine and where the field is headed in the coming years.

Obstructive Sleep Apnea Status Affects Glymphatic System Function and Cognitive Function

A recent study showed that obstructive sleep apnea may impact the long-term disruption of the glymphatic system function and the development of neurodegenerative diseases.

Doxepin Demonstrates Effectiveness to Treat Sleep Latency in Insomnia

Assessing doses of 3 mg doxepin, results revealed non-statistically significant improvements in latency to sleep onset and latency to persistent sleep that were observed across patients above and at or below the median baseline values.

Age-Dependent Risk for Neurodegenerative Disorder Identified in Obstructive Sleep Apnea

In a clinical cohort study, approximately 89% of patients with obstructive sleep apnea classified as “Probably-normal” or “Likely-normal" in assessment of sleep biomarker-based neurodegenerative disorder risk.

Understanding the Role of Sleep in the Emergence of Neurodevelopmental Disorders: Temitayo Oyegbile-Chidi, MD, PhD

The pediatric neurologist at the University of California, Davis, provided perspective on some of the mechanistic links between sleep and neurodevelopmental disorders. [WATCH TIME: 3 minutes]

SynAIRgy Phase 3 Trial Aims to Assess Pharmacological Activation of Upper Airway Muscles to Treat Obstructive Sleep Apnea

A phase 3 trial plans to investigate the efficacy and safety of AD109, a novel oral medication, for treating obstructive sleep apnea in patients who cannot tolerate continuous positive airway pressure therapy.

Adverse Events of Low-Sodium Oxybate in Idiopathic Hypersomnia Begin Early in Treatment Course

Regardless of whether patients were treatment-naïve or taking alerting agents, the safety profile of low-sodium oxybate remained true, with treatment-emergent adverse events attributing to less than 4% of study discontinuations.

Cognitive Behavioral Therapy for Insomnia Shows Promise in Pilot Trial of Epilepsy

Overall, most patients reported satisfaction with cognitive behavioral therapy approach, with completion of lessons associated with a decrease in Fatigue Severity Scale.

Emerging Treatment Approaches and Medical Devices for Obstructive Sleep Apnea: Kin Yuen, MD, MS

The sleep medicine specialist at the University of California, San Francisco provided perspective on some of the innovative therapeutic strategies in development for patients with obstructive sleep apnea. [WATCH TIME: 5 minutes]

Study Highlights Sleep Challenges and Self-Help Strategies for Pediatric Epilepsy

A recent study demonstrated no significant difference in sleep efficiency between pediatric patients with epilepsy who used self-help strategies for sleep aids and those who did not.

Depression Associated With Increased Risk of Neurodegenerative Diseases in Isolated REM Sleep Behavior Disorder

A recent study presented at SLEEP 2024 showed that depression in patients with isolated REM sleep behavior disorder significantly increased the risk of conversion to neurodegenerative diseases.

Low-Sodium Oxybate Remains Effective, Safe in Narcolepsy With Psychiatric and Neurologic Comorbidities

Those on low-sodium oxybate, regardless of psychiatric comorbidity status, outperformed placebo on a number of outcomes, including Epworth Sleepiness Scale and weekly cataplexy attacks.

Early Report Suggest Disease-Modifying Therapies May Halt Sleep-Related Disordered Breathing in Spinal Muscular Atrophy

A majority of the small cohort of patients with SMA did not need a polysomnogram at 1 year because respiratory pathology was not a concern, attributable to improvements from disease-modifying therapies.

The Complexity of Immune Cell Interactions and Potential Treatments for MS: Jenn Orthmann-Murphy, MD, PhD

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania talked about her presentation at CMSC 2024 on the complex interactions of immune cells in multiple sclerosis. [WATCH TIME: 6 minutes]

KP1077 Shows Promise as Potential Treatment for Idiopathic Insomnia in Phase 2 Trial

After 5 weeks of open-label treatment, KP1077-treated patients showed mild adverse events that were typical for a central nervous system stimulant.

Recognizing the Clinical Features of MOGAD for Diagnosis: Eoin P. Flanagan, MB, BCh

The professor of neurology at Mayo Clinic talked about how MOG antibody-associated disease can be diagnosed through specific antibody tests, highlighting its distinct clinical and MRI features. [WATCH TIME: 4 minutes]

Phase 4 PROVIDE Study Aims to Assess Presence and Concentration of Ublituximab in Breastmilk

Study establishes protocols for ublituximab use in breastfeeding patients with MS, enhancing treatment decision-making.

CD40L Inhibitor Frexalimab to be Tested in Phase 3 Trials of Relapsing MS and Non-Relapsing Secondary Progressive MS

The phase 3 trials are expected to assess the therapeutic potential of frexalimab dosed every 4 weeks in both patients with relapsing MS and non-relapsing secondary progressive MS.

Ocrelizumab Effective in Diverse Populations, Cladribine Safe After Switching DMTs, High Rates of Burnout for MS Physicians

Neurology News Network for the week ending June 1, 2024. [WATCH TIME: 4 minutes]

The Challenge of Treating Fatigue in Multiple Sclerosis: Anthony Feinstein, MPhil, PhD, FRCP

The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]

Understanding the Clinical Advantages of Cladribine and its Impacts on Oligoclonal Bands: Nicola De Stefano, MD, PhD

The professor of neurology in the department of medicine, surgery, and neuroscience at the University of Siena, gave perspective on an analysis of the MAGNIFY-MS study, in which treatment with cladribine demonstrated impacts on CNS-related pathology in MS. [WATCH TIME: 4 minutes]

Safety and Pharmacokinetic Profile of Ocrelizumab in Pediatric MS Mirrors Adult Population

In comparison with adults on ocrelizumab, pediatric patients experienced no clinical relapses and a safety profile that was similar to what was previously observed.

Survey Reveals High Burnout Rates Among Physicians in Multiple Sclerosis Across the United States

A recent survey reported a high prevalence of burnout among physicians treating patients with multiple sclerosis, highlighting long work hours as one of the key factors.

Episode 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Katherine Peters, PhD. [LISTEN TIME: 13 minutes]

Switching to Cladribine Safe and Effective in Older Persons With MS, Real-World Data Show

Within a subgroup of those older than 50 years, most patients who switched to cladribine were relapse free at follow-up, with no new safety signals observed.

Ocrelizumab Maintains Efficacy and Safety in a Diverse Relapsing MS Patient Population at 1-Year

In a new analysis of the CHIMES trial, ocrelizumab displayed a trend toward improved work productivity among minority patients with relapsing multiple sclerosis.

MAGNIFY-MS Analysis Further Demonstrates Cladribine’s Direct Impact on Central Nervous System in MS

Over a 24-month treatment period, patients on cladribine demonstrated no axonal loss evident on OCT, with reductions in cerebrospinal fluid neurofilament light and impacts on oligoclonal bands.

Understanding Silent Progression in Multiple Sclerosis: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression in multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]